Zum Inhalt springen

Atriva Therapeutics to take part in upcoming scientific and industry conferences in early 2022

  • 3 min read

Tübingen and Frankfurt (Germany), December 20, 2021 – Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today its participation in the following upcoming scientific and industry conferences:

BIO Partnering at JPM
January 10 – 14, 2022, virtually
Dr. Rainer Lichtenberger, CEO of Atriva, will be available for networking and one-on-one discussions.
https://www.bio.org/events/bio-partnering-jpm

Biotech Showcase
January 10 – 12 and January 17 – 19, 2022, virtually
Dr. Rainer Lichtenberger, Dr. Stephan Stenglein, Chief Medical Officer, and Dr. Björn Cochlovius, VP Business Development, will be available for networking and one-on-one discussions.
https://informaconnect.com/biotech-showcase/

8th Annual LSX World Conference
February 8 – 9, 2022, 133 Houndsditch, Liverpool St., London, UK
Dr. Rainer Lichtenberger will be available for networking and one-on-one discussions.
https://www.lsxleaders.com/lsx-world-congress

BIO CEO & Investor Conference
February 14 – 15, 2022, New York Marriott Marquis, New York, USA & Virtual
Dr. Rainer Lichtenberger will be available for networking and one-on-one discussions.
https://www.bio.org/events/bio-ceo-investor-conference

BIO-Europe Spring®
March 28 – 30, 2022, Basel, Switzerland, and April 4 – 6, 2022 (Digital Partnering)
Atriva Therapeutics will be available for partnering via the partneringONE platform.
https://informaconnect.com/bioeurope-spring/

About Atriva Therapeutics GmbH 

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies. It was set up by a team of leading scientists in viral research as well as proven industry experts. The company aims to develop a therapy platform to treat severe respiratory diseases induced by RNA viruses with a high unmet medical need, such as influenza and COVID-19. The Atriva lead product zapnometinib (INN, currently known as ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response in such RNA viruses. Zapnometinib is under clinical development and has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects. The Company is actively enrolling patients in a Phase II study to evaluate efficacy in hospitalized COVID-19 patients.1 A Phase II study in influenza is currently planned, as are further Phase II and III studies in COVID-19. The Company owns 11 patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for antiviral therapies. The patent life runs through 2041. Atriva Therapeutics is based in Tübingen and Frankfurt, Germany.

Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de

For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter.


Contact:
Atriva Therapeutics GmbH

Dr. Rainer Lichtenberger, CEO
+49 69 9999 162 10
+49 151 7443 3175
lichtenberger@atriva-therapeutics.com


Media and Investor Relations:
MC Services AG
Eva Bauer / Raimund Gabriel
+49 89 210 228 0
atriva-therapeutics@mc-services.eu

References:

1 RESPIRE – A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients with COVID-19.